Get the Stockscreener App
15.98
1.20%
0.19
Organon Co stock is traded at $15.98, with a volume of 1.81M.
It is up +1.20% in the last 24 hours and down -6.88% over the past month.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$15.79
Open:
$15.88
24h Volume:
1.81M
Relative Volume:
0.79
Market Cap:
$4.15B
Revenue:
$6.41B
Net Income/Loss:
$1.30B
P/E Ratio:
6.9782
EPS:
2.29
Net Cash Flow:
$646.00M
1W Performance:
+8.49%
1M Performance:
-6.88%
6M Performance:
-23.87%
1Y Performance:
+39.81%
1-Day Range:
$15.88
$16.15
1-Week Range:
$14.75
$16.29
52-Week Range:
$10.84
$23.10
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
15.98 | 4.15B | 6.41B | 1.30B | 646.00M | 2.29 |
|
LLY
Lilly Eli Co
|
788.19 | 752.65B | 40.86B | 8.37B | -2.28B | 5.4193 |
|
NVO
Novo Nordisk Adr
|
106.13 | 471.56B | 39.36B | 13.79B | 9.83B | 2.4077 |
|
JNJ
Johnson Johnson
|
155.40 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
|
ABBV
Abbvie Inc
|
183.08 | 323.72B | 55.53B | 5.12B | 15.62B | 3.65 |
|
MRK
Merck Co Inc
|
103.12 | 260.72B | 63.17B | 12.15B | 14.84B | 1.80 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Algert Global LLC Has $2.20 Million Position in Organon & Co. (NYSE:OGN) - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Organon & Co. (OGN): An Oversold Healthcare Stock to Invest In Now - Insider Monkey
Cerity Partners LLC Has $12.77 Million Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
(OGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Organon & Co. (NYSE:OGN) Stock Position Lifted by Victory Capital Management Inc. - MarketBeat
Massachusetts Financial Services Co. MA Sells 332,614 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune
Thompson Siegel & Walmsley LLC Raises Stake in Organon & Co. (NYSE:OGN) - MarketBeat
Foundry Partners LLC Takes $7.64 Million Position in Organon & Co. (NYSE:OGN) - MarketBeat
Reach For A Dream and Organon Collaborate to Launch Dream Room at Rahima Moosa Mother and Child Hospital - Media Update
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Organon partners with Egyptian Drug Authority to advance women’s health and family planning in Egypt - ZAWYA
Beddow Capital Management Inc. Raises Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Organon: 7% Yield, 4x P/E, Big Upside Potential (NYSE:OGN) - Seeking Alpha
(OGN) Proactive Strategies - Stock Traders Daily
Organon & Co. (NYSE:OGN) Shares Sold by Principal Financial Group Inc. - MarketBeat
Organon & Co. (NYSE:OGN) Stock Holdings Decreased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) - Seeking Alpha
Organon & Co (OGN) Stock Price Down 3.48% on Nov 12 - GuruFocus.com
Amalgamated Bank Sells 34,385 Shares of Organon & Co. (NYSE:OGN) - MarketBeat
Los Angeles Capital Management LLC Boosts Stake in Organon & Co. (NYSE:OGN) - MarketBeat
Acorn Financial Advisory Services Inc. ADV Takes $743,000 Position in Organon & Co. (NYSE:OGN) - MarketBeat
Van ECK Associates Corp Increases Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Philip James Wealth Mangement LLC Invests $15.39 Million in Organon & Co. (NYSE:OGN) - MarketBeat
Ex-Dividend Reminder: American Water Works, Essential Utilities Inc and Organon - Nasdaq
Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem - Yahoo Finance
Income Investors Should Know That Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon - Simply Wall St
Organon & Co (OGN) Stock Price Up 2.82% on Nov 7 - GuruFocus.com
FDA extends Organon's VTAMA cream review to March 2025 By Investing.com - Investing.com Canada
Organon & Co. (NYSE:OGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Relative Strength Alert For Organon - Nasdaq
Organon updates outlook as FDA delays VTAMA label expansion - MSN
Organon reports FDA extension of target action date of review of Vtama sNDA - TipRanks
Organon’s VTAMA Cream FDA Review Extended to 2025 - TipRanks
Organon stock on watch as FDA delays VTAMA label (OGN:NYSE) - Seeking Alpha
FDA extends Organon's VTAMA cream review to March 2025 - Investing.com
(tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older - Business Wire
Organon's SWOT analysis: stock outlook amid VTAMA potential and biosimilar growth - Investing.com
Organon & Co (OGN) Stock Price Down 6.38% on Nov 4 - GuruFocus.com
Organon & Co. (NYSE:OGN) Trading Down 4.4%Should You Sell? - MarketBeat
The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Simply Wall St
Organon China’s License and Supply Agreement with Shanghai Bao Pharmaceuticals - Global Legal Chronicle
(OGN) Technical Pivots with Risk Controls - Stock Traders Daily
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 - Yahoo Finance
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Private Management Group Inc. Has $36.23 Million Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
FDA accepts Organon BLA for Prolia/Xgeva biosimilar - MSN
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023) - Yahoo Finance
Organon & Co. (NYSE:OGN) to Issue $0.28 Quarterly Dividend - MarketBeat
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):